Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 3/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 5/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | SMO | Q99835 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CNR1 | P21554 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5266455 | 0.81 | P2RY12 (0.43) | HTR6P2RY12KDM4ESMOMEN1 | |
| SCHEMBL5270542 | 0.81 | P2RY12 (0.43) | HTR6P2RY12KDM4ESMOMEN1 | |
| SCHEMBL7050895 | 0.78 | HTR6 (0.38) | HTR6CNR2GPR55P2RY12ALDH1A1 | |
| SCHEMBL5848809 | 0.76 | MEN1 (0.58) | P2RY12ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL7062060 | 0.76 | MEN1 (0.58) | P2RY12ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL5849347 | 0.76 | MEN1 (0.58) | P2RY12ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL5849276 | 0.76 | CHRM1 (0.38) | CNR2P2RY12ALDH1A1HSD17B10SMO | |
| SCHEMBL5849281 | 0.75 | CHRM1 (0.37) | CNR2P2RY12ALDH1A1MEN1MAPT | |
| SCHEMBL5849484 | 0.74 | HTR6 (0.72) | HTR6CNR2GPR55P2RY12MEN1 | |
| SCHEMBL7064279 | 0.69 | MEN1 (0.65) | P2RY12ALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115741-B2 | 4-thieno[2,3-D]pyrimidin-4-YL piperazine compounds | ALEXION PHARMACEUTICALS, INC. | 2006-10-03 | — | — | US | disclosed |
| US-20030153556-A1 | Piperazine and homopiperazine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-08-14 | — | — | US | disclosed |
| WO-2003022214-A2 | PIPERAZINE AND HOMOPIPERAZINE COMPOUNDS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153556-A1 | Piperazine and homopiperazine compounds | HAMP, MPL, F2 | HTR6 93/4885CNR2 195/4885GPR55 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.